Gene · 481
NIH grants1,651
NIH grants whose papers are about the gene, through NIH's grant-paper links.
281 to 300 of 1,651
Download this page as JSON| Grant | Title | ATP1B1 papers | Newest fiscal year |
|---|---|---|---|
| P30ES030283 | University of Louisville Center for Integrative Environmental Health Sciences | 1 | 2024 |
| P41GM108569 | National Resource for Translational and Developmental Proteomics | 1 | 2024 |
| P42ES017198 | Puerto Rico Testsite for Exploring Contamination Threats (PROTECT) | 1 | 2024 |
| R00AG066849 | Exploring Common Biological Pathways Underlying Insulin Resistance and Alzheimer Disease using Genetic and Omic Tools | 1 | 2024 |
| R01AG015819 | Risk Factors, Pathology, and Clinical Expressions of AD | 1 | 2024 |
| R01AG066429 | Targeting emerging P2RX7 signaling pathways in animal models of Alzheimer's disease | 1 | 2024 |
| R01AI153040 | Mechanism and Fidelity of RAG mediated DNA recombination | 1 | 2024 |
| R01CA234715 | Defining and Targeting Lineage Transition Programs Operative in AR Pathway Independent Prostate Cancer | 1 | 2024 |
| R01CA244550 | Inhibitors of the G protein GNAS which drives pancreatic tumorigenesis | 1 | 2024 |
| R01CA247763 | Targeting tumor and its microenvironment using nanotherapeutics for pancreatic cancer | 1 | 2024 |
| R01CA248507 | ASO and shRNA for targeting the oncogenic transcript driving fibrolamellar hepatocellular carcinoma | 1 | 2024 |
| R01DA002812 | Determinants of Drug Preference in Humans | 1 | 2024 |
| R01DK108959 | The Paracrine Regulation of Mast Cells During Biliary/Cholangiocyte Repair and Damage | 1 | 2024 |
| R01DK121846 | Mechanisms mediating podocyte-parietal epithelial cell crosstalk in proliferative glomerulopathies | 1 | 2024 |
| R01DK129464 | Interrogating the ubiquitin pathway to understand and treat cytokine-induced beta-cell death in type 1 diabetes | 1 | 2024 |
| R01EY025799 | Activation of the Angiopoietin-Tie2/TEK Pathway to Treat Ocular Hypertension and Glaucoma | 1 | 2024 |
| R01GM024485 | Molecular Basis for Transmembrane Conduction & Signaling | 1 | 2024 |
| R01GM099836 | Defining mechanisms of AAA+ disaggregases | 1 | 2024 |
| R01GM135651 | Structure and Mechanism of Non-Homologous End Joining | 1 | 2024 |
| R01GM136976 | Structural and Functional Analyses of the Full-length Insulin Receptor (IR) and Type 1 Insulin-like Growth Factor Receptor (IGF1R) in the Liganded Active State | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/481/grants?page=15